 DALLAS, April 26, 2021 PRNewswire -- Lantern Pharma Inc. NASDAQ: LTRN, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence A.I. platform to transform oncology drug discovery and development, announced a manuscript describing the efficacy profile of LP-184 in a variety of non-small cell lung cancer models was published in Oncotarget. 